Skip to main content

Evaluating human papillomavirus vaccination programs.

Publication ,  Journal Article
Taira, AV; Neukermans, CP; Sanders, GD
Published in: Emerg Infect Dis
November 2004

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated HPV prevalence and infection rates for the population overall, by age group, by level of sexual activity within each age group, and by sex. Data were based on clinical trials and published and unpublished sources. An HPV-16/18 vaccine for 12-year-old girls would reduce cohort cervical cancer cases by 61.8%, with a cost-effectiveness ratio of 14,583 dollars per quality-adjusted life year (QALY). Including male participants in a vaccine rollout would further reduce cervical cancer cases by 2.2% at an incremental cost-effectiveness ratio of 442,039 dollars/QALY compared to female-only vaccination. Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Emerg Infect Dis

DOI

ISSN

1080-6040

Publication Date

November 2004

Volume

10

Issue

11

Start / End Page

1915 / 1923

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Uterine Cervical Neoplasms
  • Sex Factors
  • Papillomavirus Infections
  • Middle Aged
  • Microbiology
  • Male
  • Immunization Schedule
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Taira, A. V., Neukermans, C. P., & Sanders, G. D. (2004). Evaluating human papillomavirus vaccination programs. Emerg Infect Dis, 10(11), 1915–1923. https://doi.org/10.3201/eid1011.040222
Taira, Al V., Christopher P. Neukermans, and Gillian D. Sanders. “Evaluating human papillomavirus vaccination programs.Emerg Infect Dis 10, no. 11 (November 2004): 1915–23. https://doi.org/10.3201/eid1011.040222.
Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004 Nov;10(11):1915–23.
Taira, Al V., et al. “Evaluating human papillomavirus vaccination programs.Emerg Infect Dis, vol. 10, no. 11, Nov. 2004, pp. 1915–23. Pubmed, doi:10.3201/eid1011.040222.
Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004 Nov;10(11):1915–1923.

Published In

Emerg Infect Dis

DOI

ISSN

1080-6040

Publication Date

November 2004

Volume

10

Issue

11

Start / End Page

1915 / 1923

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Uterine Cervical Neoplasms
  • Sex Factors
  • Papillomavirus Infections
  • Middle Aged
  • Microbiology
  • Male
  • Immunization Schedule
  • Humans